Quantification of JAK2V617F mutation by next-generation sequencing technology.
about
Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesIDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Molecular diagnostics of myeloproliferative neoplasms.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
P2860
Quantification of JAK2V617F mutation by next-generation sequencing technology.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Quantification of JAK2V617F mutation by next-generation sequencing technology.
@en
Quantification of JAK2V617F mutation by next-generation sequencing technology.
@nl
type
label
Quantification of JAK2V617F mutation by next-generation sequencing technology.
@en
Quantification of JAK2V617F mutation by next-generation sequencing technology.
@nl
prefLabel
Quantification of JAK2V617F mutation by next-generation sequencing technology.
@en
Quantification of JAK2V617F mutation by next-generation sequencing technology.
@nl
P2093
P50
P356
P1476
Quantification of JAK2V617F mutation by next-generation sequencing technology
@en
P2093
Aline Renneville
Céline Villenet
Emna Abdelhamid
Eric Lippert
Nathalie Helevaut
Sabine Quief
Valerie Coiteux
Zohra Soua
P2860
P304
P356
10.1002/AJH.23446
P577
2013-05-13T00:00:00Z